Speaker
Dr. Ming Chen
Chief Medical Director of Department of Gynomic Medicine,Changhua Christian Hospital, Taiwan
Speaker's Biography
Dr. Chen is one of the leading experts and pioneers of reproductive genetics in Asia-Pacific. His lab has been CAP-certified since 2011 and developed a full array of reproductive genetic tests, including chromosome microarray, next-generation sequencing (such as non-invasive prenatal testing, whole-exome sequencing, and shallow sequencing for preimplantation genetic testing), and preimplantation genetic testing for monogenic disorders or aneuploidy (PGT-M or PGT-A). He sat on the editorial board of BMC Medical Genomics (SCIE), Taiwan J Obstet Gynecol (SCIE). He had guest edited special issues for other SCIE-indexed peer-review journals such as Frontiers in Genetics, Diagnostics (Basel), and a few others. He is also a Full Professor in a few universities in Taiwan, including National Taiwan University, National Tsing Hua University, National Chung Hsing University, Dayeh University, and Tunghai University. He is also sitting on the Board of Trustees in a few foundations and professional societies (for example, Taiwan Society of Human Genetics). His research focuses included high-risk pregnancy, fetal medicine, medical genetics, and evolutionary biology. Remarkably, he is the only member from Taiwan to be invited to join the famous closed-door academic elite club called Fetoscopy Group since 2012. He has published more than 150 academic papers in peer-review scientific journals since 1999 and holds a few US and Taiwan patents.
Topic
Preimplantation
Genetic Testing
Abstract
Preimplantation genetic diagnosis (PGD) is a clinically feasible technology to prevent the transmission of monogenic inherited disorders in families afflicted the diseases to the future offsprings. The major technical hurdle is it does not have a general formula for all mutations, thus different gene locus needs individualized, customized design to make the diagnosis accurate enough to be applied on PGD, in which the quantity of DNA is scarce, whereas timely result is sometimes requested if fresh embryo transfer is desired. On the other hand, preimplantation genetic screening (PGS) screens embryo with aneuploidy and was also known as PGD-A (A denotes aneuploidy) in order to enhance the implantation rates as well as livebirth rates. In contrasts to PGD, PGS is still under ferocious debate, especially recent reports found that euploid babies were born after transferring the aneuploid embryos diagnosed by PGS back to the womb and only very few randomized trials of PGS are available in the literature. We have been doing PGD and/or PGS for more than 10 years as one of the core PGD/PGS laboratories in Taiwan. Here we provide a concise review of PGD/PGS regarding its current status, both domestically and globally, as well as its future challenges. (From Professor Chen's review article published in J Formos Med Assoc 2018).
Publication from Prof. Chen's group regarding PGT indexed in SCIE:
- Chen HF et al., Gene. 2014 Sep 15;548(2):299-305. doi: 10.1016/j.gene.2014.07.039. Epub 2014 Jul 14.
- Yang YS et al., Mol Cytogenet. 2015 Jul 8;8:49. doi: 10.1186/s13039-015-0140-9. eCollection 2015.
- Ma GC et al., Mol Cytogenet. 2016 Mar 21;9:25. doi: 10.1186/s13039-016-0238-8. eCollection 2016.
- Chen M et al., Thromb J. 2016 Oct 4;14(Suppl 1):33. doi: 10.1186/s12959-016-0098-9. eCollection 2016.
- Chen HF et al., J Formos Med Assoc. 2018 Feb;117(2):94-100. doi: 10.1016/j.jfma.2017.08.006. Epub 2017 Sep 6.
- Liao CH et al., Diagnostics (Basel). 2019 Apr 23;9(2):44. doi: 10.3390/diagnostics9020044.
- Chen HF et al., Taiwan J Obstet Gynecol. 2020 Jul;59(4):489-495. doi: 10.1016/j.tjog.2020.05.004.
- Chen HL et al., Diagnostics (Basel). 2021 Dec 20;11(12):2395. doi: 10.3390/diagnostics11122395.